Detalhe da pesquisa
1.
Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas.
Lab Invest
; 102(9): 957-965, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35488033
2.
Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma.
Cancers (Basel)
; 15(8)2023 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37190302
3.
Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas.
Mol Cancer Ther
; 21(1): 89-99, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34728569
4.
Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma.
Acta Biomater
; 119: 349-359, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33186784
5.
Current Immunotherapy Approaches in Non-Hodgkin Lymphomas.
Vaccines (Basel)
; 8(4)2020 Nov 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33260966
6.
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.
Clin Cancer Res
; 26(7): 1700-1711, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31831562
7.
Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma.
Clin Cancer Res
; 25(14): 4455-4465, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31004002
8.
Combined treatment of primary vitreoretinal lymphomas significantly prolongs the time to first relapse.
Br J Ophthalmol
; 102(11): 1579-1585, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29378728